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ABSTRACT  
Purpose: The purpose of this work was to 
evaluate the association between coffee 
consumption and 10-year cardiovascular 
disease (CVD) incidence in the ATTICA Study, 
and whether this is modified by baseline the 
presence or absence of metabolic syndrome 
(MetS) at baseline. Methods: During 2001-
2002, 3042 healthy adults (1514 men and 
1528 women) living in the greater area of 
Athens were voluntarily recruited to the 
ATTICA study. In 2011-2012, the 10-year 
follow-up was performed in 2583 participants 
(15% of the participants were lost to follow-
up). Coffee consumption was assessed by a 
validated food-frequency questionnaire at 
baseline (abstention, low, moderate, heavy). 
Incidence of fatal or non-fatal CVD event was 
recorded using WHO-ICD-10 criteria and MetS 
was defined by the National Cholesterol 
Education Program Adult Treatment panel III 
(revised) criteria. Results: Overall, after 
controlling for potential CVD risk factors, the 
multivariate analysis revealed a J-shaped 
association between daily coffee drinking and 
the risk for a first CVD event in a 10-year 
period. Particularly, the odds ratio for low 
(<150 ml/d), moderate (150-250 ml/d) and 
heavy coffee consumption (>250 ml/d), 
compared to abstention, were 0.44 (95%CI: 
0.29-0.68), 0.49 (95%CI: 0.27-0.92) and 
2.48 (95%CI: 1.56-1.93) respectively. This 
inverse association was also verified among 
participants without MetS at baseline but not 
among participants with the MetS. 
Conclusions: These data supports the 
protective effect of drinking moderate 
quantities of coffee (equivalent to 
approximately 1-2 cups daily) against CVD 
incidents. This protective effect was only 
significant for participants without MetS at 
baseline. Key words: Cardiovascular 
Diseases; Metabolic Syndrome Χ; coffee; 
inflammation
 
 
1. Introduction 
Coffee is one of the most commonly consumed beverages around the world. Because of its 
popularity, investigating the association between coffee consumption and chronic disease risk has 
important public health consequences. Coffee is a complex chemical mixture, containing >1000 
bioactive compounds with potential beneficial properties, including insulin-sensitizing and anti-
inflammatory effects [1, 2].  Notably, chronic low-grade inflammation underlies the pathogenesis of all 
components of metabolic syndrome (MetS): hyperglycemia, insulin resistance, hypertension, obesity, 
and dyslipidemia, all of which are risk factors for cardiovascular disease. Therefore, dietary 
interventions designed to reduce the inflammatory procedure could be of benefit to reduce the 
cardiovascular disease (CVD) risk [3]. Existing data do support the effect of habitual coffee 
consumption on cardiovascular health. 
Since 2000, the association between coffee consumption and other CVD outcomes including 
stroke, heart failure, and total CVD mortality has been widely investigated. However, the nature of 
this association remains unclear since many prospective cohort studies reported conflicting data. A 
recent cohort study by Liu et al found that coffee consumption (4 cups/day) was associated with 
increased mortality, but the association was no longer significant for persons under 55 years old [4], 
whereas the EPIC study reported that coffee consumption was not associated with risk of CVD [5]. 
Interestingly, in 2014, a meta-analysis of 21 prospective studies and 997,464 participants (121,915 
deaths), found a non-linear dose-response relationship between coffee and CVD mortality suggesting 
that the largest risk reductions were observed for 3 cups/day for CVD mortality (21% lower risk) [2]. 
These results for coffee-CVD mortality were comparable to those reported in a previous meta-analysis 
including 36 studies and 1,279,804 participants (36,352 CVD cases) that strengthened the coffee-CVD 
non-linear U-shaped relationship, i.e. moderate coffee consumption (3-5 cups/day) was associated 
with lower CVD risk, and heavy coffee consumption (≥ 6 cups/day) was neither associated with a 
higher nor a lower risk of CVD [6].  
While current research aims to reveal the actual association between coffee consumption and CVD 
risk little is known about the potential mediators of this association. Prolonged inflammatory processes 
is closely related to oxidative stress and contribute to the pathogenesis of atherosclerosis [7,8]. 
Epidemiological data have found that coffee is associated with reduced biomarkers of oxidative stress 
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since several compounds found in coffee (polyphenols i.e. chlorogenic acid; volatile aroma compounds 
e.t.c.) contribute to its antioxidant capacity; moreover, several studies have revealed a beneficial, 
acute effect of coffee consumption on endothelial function [9, 10]. As a result, coffee drinking 
increases plasma antioxidants that can antagonize the oxidative stress and inflammation process, 
which both underlie atherogenesis and increase aortic stiffness.  
Despite the increasing understanding of the emerging role of chronic inflammation in CVD has 
stimulated research into the potential protective effect of coffee consumption, a major source of 
dietary antioxidants, the evaluation of inflammatory and oxidative stress indices on coffee-CVD 
relationship in the long-term has rarely been studied.  Furthermore, very few studies have tested the 
aforementioned association at high CVD risk people, e.g., hypertensive, diabetic [3, 11]. Therefore, 
the aim of the current work was to prospectively examine the associations of coffee consumption and 
the 10-year CVD incidence in the participants of the ATTICA study, and examine whether this is 
modified by chronic inflammation and oxidative stress status. Secondly, we wished to assess whether 
this  association was affected by the presence of MetS among apparently healthy adults. By answering 
the tested hypotheses new insights in the coffee consumption - CVD risk associations will be revealed. 
 
2. Materials and Methods 
2.1 Sampling procedure at baseline examination 
The ATTICA Study is a prospective population-based study that was carried out in the greater 
metropolitan area of Athens in Greece, which included 78% urban and 22% rural population. The 
baseline examination of the study was carried out during 2001-2002 [12]. The sampling procedure 
anticipated enrolling only one participant per household; it was random, multistage and based on the 
age, sex distribution of the Attica region (census of 2001). Of the 4056 invited individuals at baseline-
examination, 3042 agreed to participate (75% participation rate); 1514 of the participants were men 
(18-87 years) and 1528 were women (18-89 years). All participants were interviewed by trained 
personnel (cardiologists, general practitioners, dieticians and nurses) who used a standard 
questionnaire. Exclusion of CVD at baseline evaluation was performed through a detailed clinical 
evaluation by the physicians of the study. The examination was performed in the individuals’ homes or 
workplaces. 
2.2 Baseline measurements 
The baseline evaluation included information about demographic characteristics (age, sex), personal 
history of hypertension, hypercholesterolemia and diabetes, dietary and other lifestyle habits (i.e., 
smoking status, physical activity, education). In the present analysis, smoking was defined through 
years of smoking while education was measured in years of school. The evaluation of the dietary 
habits was based on a validated semi-quantitative food-frequency questionnaire [13], the EPIC-Greek 
questionnaire that was kindly provided by the Unit of Nutrition of Athens Medical School. On the basis 
of the FFQ, all participants were asked about their usual frequency (average) of daily coffee 
consumption.  
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The MedDietScore was also applied (range 0-55) to evaluate adherence to the Mediterranean 
diet [14]. For the ascertainment of physical activity status the International Physical Activity 
Questionnaire was used (IPAQ) [15], as an index of weekly energy expenditure using frequency 
(times per week), duration (in minutes per time) and intensity of sports or other habits related to 
physical activity (in expended calories per time). Participants who did not report any physical activities 
were defined as physically inactive. Waist circumference was measured in the middle between the 
lowest rib and the iliac crest using an inelastic measuring tape to the nearest 0.5 cm, while waist to 
hip ratio was also calculated. Arterial blood pressure (mean of 3 recordings) was measured at the end 
of the baseline physical examination in a sitting position after resting for at least 30 minutes. 
Participants whose average blood pressure levels were greater or equal to 140/90 mmHg or were 
under antihypertensive medication were classified as having hypertension. Blood samples were 
collected from the antecubital vein between 8 to 10 am, in a sitting position after 12 hours of fasting 
and alcohol abstinence. Blood lipids (total cholesterol, HDL-cholesterol) and triglycerides were 
measured using chromatographic enzymic method in a Technicon automatic analyser RA-1000 (Dade 
Behring, Marburg, Germany). Hypercholesterolemia was defined as total cholesterol levels greater 
than 200 mg/dl or the use of lipids lowering agents. Blood glucose levels (mg/dl) were measured with 
a Beckman Glucose Analyzer (Beckman Instruments, Fullerton, CA, USA). Diabetes mellitus (type 2) 
was defined according to the American Diabetes Association diagnostic criteria (i.e., blood glucose 
levels greater than 125 mg/dl classified participants as having diabetes) [16]. Participants were 
classified as having the MetS or not, according to the NCEP ATP III (revised 2005) definition. MetS 
presence was defined if three or more of the following metabolic syndrome components were present: 
waist circumference 102 cm for males or 88 cm for females; triglyceride level 150 mg/dl; HDL 
cholesterol level <40 mg/dL for males or <50 mg/dL for females; blood pressure 130/85 mmHg; 
fasting blood glucose 100 mg/dL [17]. 
High sensitivity C-reactive protein was assayed by particle-enhanced immunonephelometry 
(N Latex, Dade-Behring Marburg GmbH, Marburg, Germany). Participants with chronic inflammation 
or CRP levels above 10 mg/L were not included in the analyses. Furthermore, inflammatory markers, 
such as homocysteine, fibrinogen, Interleukin-6 (IL-6)), and oxidative stress markers (plasma 
oxidized LDL-cholesterol (ox-LDL)), were also measured. 
2.3 Coffee consumption 
All participants were asked about average coffee drinking habits during the preceding year. 
Consumption of all reported types of coffee (i.e., instant coffee, brewed coffee, Greek-type coffee, 
cappuccino or filtered coffee) were recorded in cups of coffee per day (1 cup = 150 ml) and then 
recalculated (in ml), after adjustment for 28% caffeine containment [18] for analytical reasons. Thus, 
after this re-calculation, 1 “adjusted” cup of coffee (i.e., 150 ml) could be equivalent to 450 ml 
Table 1 Demographic and clinical characteristics of the n = 2020 participants by daily coffee consumption. 
  Daily coffee consumption (ml/d) P1 
 Never 
0 
(n=342) 
Low  
0-150 
(n=1126) 
Moderate 
150-250 
(n=338) 
High 
>250 
(n=214) 
 
10-year incidence of CVD, % 19 16 7 25 <0.001 
Demographic, lifestyle and clinical characteristics 
Age (years)  50 ± 14 46 ± 13 36 ± 12 50 ± 13 <0.001 
Gender, % male 26 45 66 77 <0.001 
Smoking (years) 20 ± 11  20 ± 12 16 ± 10 23 ± 11 <0.001 
Physical activity, % 36 40 41 39 0.38 
Waist to hip ratio 0.83 ± 0.09 0.86 ± 0.11 0.86 ± 0.10 0.92 ± 0.12 <0.001 
Education (years of school) 12 ± 3 12 ± 4 13 ± 3 12 ± 4 <0.001 
Hypertension, %yes 29 31 21 38 <0.001 
Diabetes Mellitus, %yes 7 8 3 10 <0.001 
Hypercholesterolemia, %yes 52 37 29 55 <0.001 
MedDietScore (range 0-55) 25 ± 6 26 ± 7  27 ± 7 24 ± 6 <0.001 
Metabolic Syndrome, %yes 21 21 14 24 <0.001 
Oxidative and Inflammatory biomarkers 
Oxidised LDL-C (mg/dL) 72 ± 21 49 ± 23 63 ± 30 83 ± 22 <0.001 
Interleukin-6 (ng/mL) 1.5 ± 0.7 1.5 ± 0.5 1.4 ± 0.3 1.5 ± 0.8 <0.001 
C-reactive protein (mg/L) 2.1 ± 2.5 2 ± 2.5 1.8 ± 2.3 1.8 ± 2.1 0.15 
Homocysteine (μmol/L) 11 ± 4 12 ± 6 12 ± 7 13 ± 5 0.03 
Fibrinogen (mg/dL) 331 ± 78  314 ± 69 288 ± 61 319 ± 67 <0.001 
1p values for the comparisons between coffee drinking categories derived using the t test, while for the comparisons of 
categorical variables using the chi square test. 
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brewed coffee or 300 ml instant coffee. According to the observed distribution of coffee drinking 
pattern, four coffee consumption categories were created: abstention, low (0-150 ml/day), moderate 
(150-250 ml/day) and high (>250 ml/day). Information of decaffeinated coffee drinking was also 
recorded, but not used in the analysis because of the very small number of participants reported 
drinking this type of coffee (n=47). 
2.4 Follow-up examination (2011-2012) 
During 2011-12, the ATTICA Study’s investigators performed the 10-year follow-up (mean 
follow-up time 8.41 y) [19]. Of the n=3042 initially enrolled participants, n=2583 were found during 
the follow-up (85% participation rate). Mean age at baseline (±SD) was 45±14 and 46±14 years for 
women and men respectively (no difference with the overall sample). Of the individuals that were lost 
to follow-up (i.e., n=459), n=224 were not found because of missing or wrong addresses and 
telephone numbers that they have provided at baseline examination and n=235 because they denied 
being re-examined. Regarding CVD evaluation at follow-up clinically accurate data were obtained from 
n=2020 participants. In order to participate in the follow-up all participants were initially contacted 
through telephone calls. Afterwards, the investigators approached the n=2583 participants that were 
allocated in the follow-up and performed a detailed evaluation of their medical records. In particular, 
from June 2011 to June 2012 information about participants': (a) vital status (death from any cause 
or due to CVD), (b) development of CHD (i.e., myocardial infarction, angina pectoris, other identified 
forms of ischemia -WHO-ICD coding 410-414.9, 427.2, 427.6-, heart failure of different types, and 
chronic arrhythmias -WHO-ICD coding 400.0-404.9, 427.0 -427.5, 427.9-), (c) development of stroke 
(WHO-ICD coding 430-438). The working sample size was adequate to achieve 92% statistical power 
to evaluate relative risk of 0.70 between the null and the alternative two-sided hypothesis, when the 
exposure variable (i.e., coffee drinking category) was increased by 1-unit and with a significance level 
(alpha) of 0.05 
2.5 Bioethics 
The study was approved by the Bioethics Committee of Athens Medical School and was 
carried out in accordance to the Declaration of Helsinki (1989) of the World Medical Association. Prior 
to the collection of any information, participants were informed about the aims and procedures of the 
study and provided their written signed consent. 
2.6 Statistical analysis 
Crude, non-fatal and fatal incidence rates of combined CVD (i.e., CHD or stroke) were calculated as 
the ratio of new cases to the number of people participated in the follow-up. Incidence by coffee 
drinking status was calculated as the ratio of new cases in each coffee category to the number of 
participants in the same category. The continuous variables were tested for normality through P-P 
plots and presented as mean values ± standard deviation or as median (1st, 3rd quartile) if not 
normally distributed while categorical variables were presented as relative frequencies. Associations 
between categorical variables were tested using the chi-square test, while between continuous 
variables using Pearson r or Spearman’s rho coefficients, for the normally and skewed variables 
respectively. Comparisons of mean values of normally distributed variables by coffee drinking status 
were performed using analysis of variance (ANOVA) and post-hoc analyses using Bonferroni rule were 
performed to account for the inflation of the probability of type-I error. Comparisons between mean 
values of normally distributed variables between those who developed an event and the rest of the 
participants were performed using Student’s t-test, after controlling for equality of variances using the 
Levene’s test. Comparisons of continuous variables that did not follow the normal distribution were 
performed using the non-parametric U-test proposed by Mann and Whitney and the Kruskal-Wallis H-
test. The hazard ratios (HR) and the corresponding 95% confidence intervals (CI) of developing a CVD 
event during the 10-year period, according to the participants’ baseline characteristics were estimated 
using Cox proportional hazards models. The time to CVD event was recorded on annual basis. 
Furthermore, non-linear trend analysis was applied in order to evaluate curve fitting on the effect size 
measures (hazard ratios) between coffee drinking categories and the outcome. Trend analysis was 
applied by fitting smoothing lines (linear, quadratic or cubic) on the odds ratios derived by age-sex 
adjusted analysis, by coffee drinking category (coffee was categorized in 4 categories to perform this 
analysis, abstention, 0-150 ml, 150-250 ml, >250 ml); the corresponding R-squared values indicated 
which line best fit the observed data. All reported p-values are based on two-sided tests. SPSS version 
21 (Statistical Package for Social Sciences, SPSS Inc, Chicago, IL, U.S.A.) software was used for all 
the statistical calculations. 
 
3. Results 
3.1 Ten-year CVD incidence 
The 10-year fatal or non-fatal CVD event rate was 157 cases/ 1000 participants (n=317), 198 being in 
males (198 cases/ 1000 participants) and 119 being in females (117 cases/ 1000 participants) (p for 
gender difference <0.001).  
 
Table 2. Results from the multi-adjusted Cox proportional hazards models that were developed to evaluate the 10-
year risk of having a cardiovascular event (outcome) according to the daily coffee consumption among ATTICA 
study participants (n=2020). 
All participants  Hazard Ratios (HR), 95% Confidence Intervals 
 Model 1 Model 2 Model 3 
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3.2 Participants’ baseline characteristics by coffee drinking status 
Baseline characteristics of the studied sample, by adjusted coffee drinking status (0, 
<150ml/d, 150-250ml/d, >250 ml/d), are presented in Table 1. As it can be seen, compared to 
abstainers, the group of participants, who were drinking daily lower amounts of coffee up to 1 
adjusted cup (<150 ml/d), included younger men, with increased waist to hip ratio, with increased 
arterial blood pressure and glucose, and decreased levels of blood lipids, who adhered closer to the 
Mediterranean diet, (all p-values <0.001). Similarly, subjects drinking 1 to 2 adjusted cups of coffee 
(150-250 ml/d), compared to coffee non-drinkers, were more likely to be younger male participants, 
lighter smokers, more strongly adhering to the Mediterranean diet (i.e. higher MedDietScore, mean 
score of 27/55), but also less likely to have a history of hypertension, diabetes, hypercholesterolemia 
and therefore MetS. Finally, those reporting drinking over 2 adjusted cups of coffee daily (>250 ml/d) 
when compared to abstainers were the most likely to be male, heavier smokers, obese, lower 
adherers to the Mediterranean diet, with increased susceptibility to hypertension, diabetes mellitus, 
hypercholesterolemia and MetS. No significant differences were observed out as regards physical 
activity levels (p=0.38). 
Mean circulating concentrations of participants’ inflammation state characteristics, by coffee 
consumption categories, are also shown in Table 1. Overall, participants who consumed low and 
moderate amounts of coffee daily (barely 1-2 cups of coffee) had on average lower ox-LDL, lower 
fibrinogen but higher homocysteine concentrations, compared to coffee abstainers. Similar results 
were extracted for fibrinogen and homocysteine levels for heavy coffee drinkers, consuming over 2 
cups of coffee daily, but not for ox-LDL levels which were increased. As for the rest of the 
inflammatory biomarkers, IL-6 was comparable among the 4 groups, while CRP levels did not differ 
significantly by coffee drinking status (p=0.15).  
3.3 10-year CVD incidence and coffee drinking 
 The 10-year incidence of CVD (Table 1) was n=60 (19%) among coffee abstainers, n=175 
(16%) among participants who consumed lower amounts of coffee, n=23 (7%) among moderate 
drinkers and n=54 (25%) among heavy coffee drinkers (p<0.001). Based on these rates a trend 
analysis was applied; a J-shape association was revealed (p for parabolic trend = 0.05).  
 
 
However, all the afore mentioned comparisons may be prone to bias due to potential factors; 
therefore multi-adjusted analysis was performed, controlling for various CVD covariates (see Table 
2). Age-sex adjusted analysis revealed a significant association between coffee drinking and CVD 
incidence (Table 2, Model 1); and a J-shape trend was evident (p<0.05). When personal and 
behavioral characteristics were taken into consideration (i.e., waist to hip circumference ratio, ever 
smoking, physical activity status, education and adherence to the Mediterranean diet), drinking 1-2 
cups of coffee/d was inversely associated with CVD incidence compared to abstention, whereas 
drinking > 2 cups of coffee daily was associated with increased risk of CVD events (Table 2, Model 
2); still J-shape trend was evident even after adjusting for the aforementioned lifestyle behaviors. The 
aforementioned findings regarding the J-shaped trend of coffee drinking on CVD risk remained 
significant even after controlling for the classical CVD risk factors (i.e., hypertension, diabetes, 
hypercholesterolemia) (Table 2, Model 3). Moreover, and in order to further take into account the 
Age (per 1 year) 1.01 (1.08-1.10) 1.07(1.05-1.10) 1.06 (1.04-1.09) 
Men vs. Women 2.13 (1.59-2.86) 2.01 (1.19-3.40) 1.99 (1.16-3.42) 
Coffee drinking    
Low coffee drinkers vs. abstainers 0.47 (0.32-0.71)2 0.47 (0.31-0.72)2 0.44 (0.29-0.68)2 
Moderate coffee drinkers vs. abstainers 0.58 (0.31-1.04)2 0.53 (0.29-0.97)2 0.49 (0.27-0.92)2 
High coffee drinkers vs. abstainers 2.81 (1.84-4.23)2 2.62 (1.67-4.09)2 2.48 (1.56-1.93)2 
Smokers vs. non smokers - 1.00 (0.98-1.02) 1.00 (0.98-1.02) 
Physically activity vs. inactive - 0.68 (0.45-1.02) 0.68 (0.45-1.04) 
Waist to hip ratio - 8.7 (0.95-80) 3.86 (0.38-39) 
Education (years of school) - 0.97 (0.92-1.02) 0.98 (0.92-1.03) 
MedDietScore (range 0-55) - 0.96 (0.93-1.001) 0.96 (0.93-0.99) 
Hypertension (y/n) - - 1.13 (0.74-1.70) 
Diabetes Mellitus (y/n) - - 2.4 (1.33-4.40) 
Hypercholesterolemia (y/n) - - 1.42 (0.95-2.13) 
Table 3. Results from the additive Cox proportional hazards models that were developed to 
evaluate the mediating role of oxidative and inflammatory markers on the association between 
coffee consumption and the risk of 10-year cardiovascular disease events (outcome). 
 Hazard Ratios (HR)2, 95% CI for coffee consumption  
 Low vs. Never Moderate vs. Never High vs. Never 
Full Model 1 0.44 (0.29-0.68) 0.49 (0.27-0.92) 2.48 (1.56-1.93) 
Full Model 1+ C-reactive protein 0.46 (0.24-0.89) 0.42 (0.18-0.98) 1.60 (0.74-3.46) 
Full Model 1+ Oxidised LDL-C 0.34 (0.12-0.95) 0.19 (0.05-0.83) 1.26 (0.46-3.46) 
Full Model 1+ Interleukin-6 0.49 (0.25-0.95) 0.43 (0.18-0.99) 1.62 (0.76-3.45) 
Full Model 1+ Homocysteine 0.57 (0.24-0.98) 0.50 (0.18-0.97) 1.76 (0.66-4.72) 
Full Model 1+ Fibrinogen 0.42 (0.21-0.82) 0.32 (0.13-0.75) 1.56 (0.69-3.51) 
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role of smoking, a restricted analysis only among never smokers was applied and revealed a similar 
trend of coffee drinking on CVD risk (HR, 95%CI for abstainers/low/moderate/high coffee drinkers: 1 
(Reference), 0.46 (0.27, 0.77), 0.49 (0.21, 1.18) and 3.15 (1.86, 5.14), respectively). Coffee intake 
might also be confounded by specific dietary habits, i.e., intakes of fruits, juices and sugar sweetened 
beverages; additional analysis based on Model 3 (Table 2) showed that the J-shaped trend of coffee 
drinking on CVD risk remained significant even after controlling for the aforementioned covariates 
(HR, 95%CI for abstainers/low/moderate/high coffee drinkers: 1 (Reference), 0.48 (0.32, 0.73), 0.62 
(0.34, 1.11) and 2.85 (1.86, 4.38), respectively). Additionally, taking into account that the ATTICA 
study had previously shown a dose-response relation between coffee consumption and inflammatory 
markers (C-reactive protein, interleukin-6, oxidative - LDL, homocysteine) [20], the latter biomarkers 
were entered consecutively and separately in the latest fully adjusted Model 3; no alterations as 
regards the observed J-shaped trend of coffee drinking on CVD risk were found.  
 Notably, a significant interaction was observed between coffee drinking and presence of MetS 
on 10-year CVD risk (p for interaction = 0.012). This was also supported by the significant association 
observed between quantity of coffee drinking and prevalence of MetS (Table 1). Thus, the analysis 
was repeated by MetS group at the baseline examination. Based on the additional stratified analysis, it 
was observed that low and moderate daily coffee consumption compared to coffee abstention 
remained significantly protective against CVD risk among participants who did not have MetS at 
baseline (OR for 0-150ml daily vs. abstainers =0.26;95% CI: 0.16, 0.54, HR for 150-250ml daily vs. 
abstainers =0.18;95% CI: 0.06, 0.52); however coffee consumption was not associated with 10-year 
CVD risk among participants with MetS. 
4. Discussion 
The present study demonstrated a J-shaped association between coffee consumption and the 10-year 
CVD incidence. In particular, low and moderate coffee consumption (150-250 ml coffee/d), was 
associated with 56% and 51% lower CVD risk respectively, compares to abstention, whereas heavy 
consumption (>250 ml coffee/d) was associated with a significant 2.5-fold increase in risk, 
independently of the known potential confounders including lifestyle factors and clinical 
characteristics. However, in an effort to identify potential mediators of the above mentioned 
association we failed to identify any of the known inflammatory biomarkers as having such a 
mediating effect. The protective effect of consuming daily 1-2 cups of coffee daily was significant in 
the overall sample and among MetS free participants but not in high-CVD risk individuals (i.e MetS 
subjects), indicating that atherosclerotic mechanisms have already been triggered in earlier stages of 
their life and have, thus possibly neutralizing the protective effect of coffee on CVD risk [21-23]. In 
any case, the reported findings offer a considerable message for public health i.e. long-term low and 
moderate daily coffee drinking may be of benefit on 10-year risk for CVD, whereas heavy consumption 
is associated with significantly increased risk in healthy adults. 
 A potential biological mechanism for the inverse association of low and moderate coffee 
consumption with 10-year CVD incidence may be related, according to recent studies, to the fact that 
coffee is a source of antioxidants that may influence oxidative stress and endothelium function [3,24]. 
An imbalance of antioxidant defences and the production of reactive oxygen species can contribute to 
the pathogenesis and progression of atherosclerosis via various pathways [25, 26]. During 
inflammation, the produced, by active NADPH oxidase, superoxide (O2
-) leads to other reactive oxygen 
species. Apart from the respiratory burst, mitochondrial electron transport chain during inflammation 
produces extra O2
- that generates oxidative stress [27]. Chlorogenic acid (CGA) is the most prevalent 
polyphenol in coffee and has high bioavailability. Moreover, recent data support that polyphenols offer 
protection by stimulating endogenous antioxidant defence systems through specific gene response 
elements that are inducible by oxidative stress [28, 29].  In the context, CGA, the most highly 
prevalent polyphenol in coffee, may play a key role in acutely raising the plasma antioxidant capacity 
in healthy adults, thereby lowering the risk of atherosclerosis [30, 31]. 
 The observed J-shaped association between coffee consumption and CVD risk (i.e., 
low/moderate consumption seems beneficial, whereas increased consumption may be harmful) can 
also be based on other plausible biological mechanisms. In particular, coffee is a composite brew with 
several bioactive compounds including caffeine, CGA, diterpene alcohols, minerals such as potassium 
and magnesium, niacin and lignans [1]. Several studies have concluded that coffee has been inversely 
associated with diabetes risk and CRP levels [9, 10]. However, caffeine in higher concentrations has 
been associated with acute increases in blood pressure and adverse effects on arterial stiffness and 
endothelium dependent vasodilation [6]. Furthermore, long-term heavy coffee consumption has been 
associated with risk of hypertension and higher homocysteine levels [11]. Thus, it remains to be 
further studied if the association between coffee and homocysteine levels explains the J-shaped 
association. It is therefore possible that with low and moderate coffee consumption, beneficial effects 
may be greater, whereas with heavy coffee consumption, negative effects may counterbalance the 
positive ones. 
 To our knowledge, based on a large sample of healthy subjects, this prospective study is one 
of the few in the literature that suggests a J-shaped association between coffee consumption and the 
risk of developing CVD [2, 4-6]. Until recently case-control studies have reported a J-shaped relation 
between coffee consumption and the risk of CVD [10, 32]. In accordance with our findings the Greek 
CARDIO2000 case-control study examined the association between coffee consumption and the risk of 
developing acute coronary syndromes based on a large sample of coronary patients and CVD-free 
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controls. After controlling for the presence of known CVD confounders, the analysis raised a J-shaped 
association between the quantity of coffee consumed per day and the risk of developing acute 
coronary syndromes. Moderate coffee consumption (<300 ml coffee/d), was associated with a lower 
coronary risk, whereas heavy or very heavy consumption (>300 ml/d) was associated with a 
significant increase in risk [32]. This result may explain partially the contradictory results reports by 
earlier studies. 
 Although many studies in the past have attempted to assess the role of coffee consumption 
on CVD incidence, the findings remain inconsistent mainly as a result of the different study designs. 
With the exception of few studies, a recent meta-analysis of prospective cohort studies has concluded 
that moderate coffee (3-5 cups/d) consumption was inversely significantly associated with CVD risk, 
while heavy consumption was not, demonstrating a non-linear U-shaped association [6]. However, 
residual confounding by smoking may have biased the association for heavy coffee drinkers (higher 
prevalence of cigarette smoking) upward. The U- or J-shaped association could be attributed to the 
coffee’s preparation: at higher intakes of coffee prepared, the intake of atherogenic coffee lipids may 
outweigh the potentially beneficial micronutrient compounds of coffee. Cohort studies generally 
showed a null association. Differences among studies in sample sizes, the characteristics of the study 
populations, the assessment methods for coffee consumption, and the statistical adjustments may 
have contributed to divergent results [33]. Since the true association between coffee consumption and 
CVD risk is likely to be modest and non linear, the differences in coffee assessments and covariate 
adjustments may result in changing the magnitude and even the direction of the associations and thus 
lead to different conclusions.  
 The major strengths of the present study are its prospective design, the large sample size 
from general population and a long period of follow up (10-years), which  allowed us to assess the 
incidence of several outcomes. It is the first prospective study suggesting a J-shaped association 
between coffee consumption and 10-year CVD incidence, compared to case-control studies where 
recall biases affect their results. Another advantage of our study was that we conducted a first-event 
dose-response analysis which provides a comprehensive description of the shape of low/moderate and 
heavy coffee consumption that can be proved to be cardioprotective or detrimental for cardiovascular 
health. Particularly, our study is one of the few that extracted significant protective results for 
minimum daily coffee quantities reaching barely 1-2 cups of coffee that can contribute to the CVD 
prevention. Furthermore, our results remained significant when potential CVD confounders were taken 
into consideration among participants with or without the MetS; a condition that poses individuals by 
default at high CVD risk. In this work it was confirmed that low and moderate coffee consumption may 
reduce CVD risk among people at low risk, whereas focusing on high CVD risk individuals (e.g. with 
MetS) the protective effect of this habit seems to disappear. This carries a specific health message, 
since the adoption of dietary habits are more likely to reflect real practices of generally healthy 
individuals trying to reverse the results of several decades of oxidative stress. 
4.1 Limitations 
However, some limitations of the study should be acknowledged. Firstly, coffee consumption 
was assessed by FFQ at the time of recruitment and relied on participants’ self report even though, 
results from dietary validation studies suggest that the use of FFQ for coffee self-report assessment is 
highly reproducible and agrees well with assessments using diet records [34]. Secondly, the number 
of cases is relatively few, but according to our statistical power analysis a-posteriori the achieved 
power was enough to evaluate the observed associations in our results. Furthermore, some 
participants may have changed their coffee habits during the long follow-up of 10 years, but the same 
research methodology has been widely used in prospective studies, thus, the results are comparable. 
As previously described, filtering may alter coffee’s metabolic effects. The method of coffee 
preparation was not assessed in our study in our study population, and we were therefore not able to 
study whether the association between coffee consumption and CVD depends on the filtering of 
coffee. Next, we did not include information of decaffeinated coffee drinking which was also recorded, 
but not used in the analyses because of the very small number of participants reported drinking this 
type of coffee (n=47).  
4.2 Conclusions 
 Our findings provide an important public message, since moderate coffee appears to be 
beneficial on long-term CVD prevention, whereas heavy consumption is associated with significant 
increase of the 10-year CVD risk. The present study suggests a J-shaped coffee-CVD association that 
may partially explain the contradictory findings reported by previous studies. Interestingly, none of 
the inflammatory factors, speculated to mediate the coffee CVD association, seemed to modify 
significantly the association we observed. Finally, our findings that among subjects with MetS and 
hence after several years of exposure to oxidative stress, the protective effect of low to moderate 
coffee consumption against CVD was lost, suggests that it can only have such beneficial/preventive 
effects if such a habit is acquired at a relatively young age.   
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